iBody Inc. is a start-up company launched from Nagoya University, Japan, at Feb 2018.
We have pioneered a unique technology of discovering, generating, and producing monoclonal antibodies from single B cells.
Our mission is to contribute human healthcare by lightning monoclonal antibody development.
102 Incubation Facility, Nagoya University,
1 Furo-cho, Chikusa-ku, Nagoya, Aichi 464-0814, JAPAN
Feb. 1st, 2018
Teruyo Ojima-Kato Ph.D.
Hideo Nakano Ph.D. (Professor)
Yoshihiro Kakeji Ph.D. (Professor, Kobe University)
Shun'ichi Kuroda Ph.D. (Professor, Osaka University)
Kouhei Tsumoto Ph.D. (Professor, The University of Tokyo)
•Screening and Licensing of rabbit monoclonal antibodies for research and diagnostics uses.
•Screening and Licensing of human monoclonal antibodies.
Currently we are accepting collaborative research on discovering rabbit monoclonal antibodies and exploring human monoclonal antibodies.
For more details, contact us through an inquiry form or email.